Market Place
Sourcing Support
Natco submits ANDA with USFDA for Risdiplam for Oral solution
21 Nov 2024 //
BUSINESS STD
FDA Confirms Para IV Patent Litigation for Evrysdi
21 Oct 2024 //
FDA
Roche`s Evrysdi Shows Positive Results In Children With SMA
14 Oct 2024 //
GLOBENEWSWIRE
Roche`s Evrysdi Spinal Muscular Atrophy 5-Year Data Positive
07 Jun 2024 //
GLOBENEWSWIRE
PTC Announces Evrysdi Agreement with Royalty Pharma for Up To $1.5 Billion
20 Oct 2023 //
PR NEWSWIRE
England to rollout world-first seven-minute cancer treatment jab
30 Aug 2023 //
REUTERS
CHMP recommends Roche’s Evrysdi for babies under two months
22 Jul 2023 //
GLOBENEWSWIRE
CHMP Recommends Evrysdi® for Babies Under Two Months Old with SMA
21 Jul 2023 //
PR NEWSWIRE
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase Number
30 Jun 2023 //
BUSINESSWIRE
Roche pads case for Evrysdi in previously treated SMA patients
13 Oct 2022 //
FIERCEPHARMA
Positive new data for Roche’s Evrysdi in largest trial ever undertaken patients
11 Oct 2022 //
GLOBENEWSWIRE
Roche SMA drug approved in youngest infants, challenging Novartis and Biogen
01 Jun 2022 //
BIOPHARMADIVE
New 3 Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements
29 Apr 2022 //
BUSINESSWIRE
Genentech to Present Data Across Neuroscience Portfolio at 2022 AAN
24 Mar 2022 //
BUSINESSWIRE
New data for Roche`s Evrysdi demonstrate long-term efficacy and safety
16 Mar 2022 //
GLOBENEWSWIRE
Evrysdi nabs speedy review in SMA patients younger than 2 months
26 Jan 2022 //
FIERCEPHARMA
Roche nabs priority review for Evrysdi
25 Jan 2022 //
PRESS RELEASE
Genentech’s Evrysdi Granted Priority Review for Pre-Symptomatic Babies With SMA
25 Jan 2022 //
BUSINESSWIRE
NICE recommends risdiplam for spinal muscular atrophy
23 Nov 2021 //
PHARMATIMES
U.K. delays nod for Evrysdi but makes it available to patients
20 Nov 2021 //
PHARMAPHORUM
Babies with SMA able to swallow with Evrysdi treatment
24 Sep 2021 //
EPR
Roche presents new data at World Muscle Society (WMS) 2021 highlighting
24 Sep 2021 //
GLOBENEWSWIRE
Biogen Plans to start Phase 3b Study of High Dose Nusinersen
15 Sep 2021 //
GLOBENEWSWIRE
Biogen to Initiate PIIIb for Evaluating potential of Higher Dose of Nusinersen
15 Sep 2021 //
BIOSPACE
Evrysdi (risdiplam) Receives CADTH Reimbursement Recommendation
30 Aug 2021 //
NEWSWIRE
Chugai introduces Evrysdi dry syrup 60 mg to treat spinal muscular atrophy
12 Aug 2021 //
PHARMABIZ
Chugai introduces Evrysdi dry syrup 60 mg to treat spinal muscular atrophy
12 Aug 2021 //
PHARMABIZ
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function
11 Jun 2021 //
BUSINESSWIRE
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function
11 Jun 2021 //
BUSINESSWIRE
Genentech`s Evrysdi Improves Motor Function in Pre-Symptomatic Babies
10 Jun 2021 //
BUSINESSWIRE
NICE rejects risdiplam for treating spinal muscular atrophy
02 Jun 2021 //
PHARMAFILE
Health Canada Authorizes EVRYSDI (risdiplam) for the treatment of (SMA)
15 Apr 2021 //
BIOSPACE
PTC’s Evrysdi improves motor function and survival in infants with SMA
15 Apr 2021 //
CLINICALTRIALSARENA
Roche touts 2-year efficacy data for SMA therapy Evrysdi; NIH funds
15 Apr 2021 //
ENDPTS
Roche’s Evrysdi drug for SMA shown to significantly increase survival
14 Apr 2021 //
PHARMAFILE
PTC Therapeutics Announces Commercial Milestone Payment Following
01 Apr 2021 //
PRNEWSWIRE
Roche, Novartis approvals in Europe signal more head-to-head competition
30 Mar 2021 //
PRESS RELEASE
Roche`s Evrysdi wins EU approval for spinal muscular atrophy
29 Mar 2021 //
NASDAQ
Takeda takes a swing at RNA small molecules with discovery pact
23 Mar 2021 //
ENDPTS
New 2-Year Data Show Genentech’s Evrysdi (risdiplam) Continues
16 Mar 2021 //
BUSINESSWIRE
Results from the Second Year of Evrysdi™ (risdiplam)
16 Mar 2021 //
PRNEWSWIRE
EMA Recommends Oral Treatment for SMA
03 Mar 2021 //
PHARMTECH
Evrysdi leads latest CHMP recommendations
01 Mar 2021 //
PHARMATIMES
CHMP’s February recommendations: Evrysdi, Jemperli, and a generic
26 Feb 2021 //
RAPS
Roche announces results from Evrysdi study in infants with Type 1 (SMA)
25 Feb 2021 //
PRESS RELEASE
Risdiplam in Type 1 Spinal Muscular Atrophy
25 Feb 2021 //
NEJM
Genentech Announces Results From Evrysdi (risdiplam) Study in Infants
24 Feb 2021 //
BUSINESSWIRE
Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants
24 Feb 2021 //
PRNEWSWIRE
Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment
21 Oct 2020 //
PRNEWSWIRE
Roche touts 2-year Evrysdi data as oral SMA drug drives early interest
29 Sep 2020 //
FIERCEPHARMA
Genentech Presents New Data for Evrysdi (risdiplam) in Infants With Type 1 SMA
28 Sep 2020 //
BUSINESSWIRE
Novartis` Zolgensma expansion hit FDA roadblock, giving Biogen& Roche a reprieve
24 Sep 2020 //
FIERCE PHARMA
Roche says two-thirds of Evrysdi patients had got rival treatments
15 Sep 2020 //
REUTERS
PTC Therapeutics Achieves $20M Roche Milestone
27 Aug 2020 //
CONTRACTPHARMA
PTC Announces First Commercial Milestone Payment U.S. FDA Approval of Evrysdi™
26 Aug 2020 //
PRNEWSWIRE
PTC Announces First Commercial Milestone Payment UUS FDA Approval of Evrysdi™
26 Aug 2020 //
PRNEWSWIRE
EU regulators to review Evrysdi for SMA
17 Aug 2020 //
PHARMATIMES
PTC Announces the Acceptance of the EU Marketing Authorization for Evrysdi™
17 Aug 2020 //
PRNEWSWIRE
